64194-18-9

Upstream product

• 1824-81-3 2-Amino-6-methylpyridine 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 2216-94-6 phenylpropynoic acid ethyl ester 
• 83053-89-8 N-benzylidene-N-(6-methylpyridin-2-yl)amine 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 67473-56-7 4-chloro-7-methyl-2-phenyl-1,8-naphthyridine 
• 85808-53-3 9-[1-Dimethylamino-meth-(E)-ylidene]-6-methyl-4-oxo-2-phenyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde 
• 85808-59-9 3,9-diformyl-6-methyl-2-phenyl-6,7,8,9-tetrahydro-4H-pyrido<1,2-a>pyrimidin-4-one 
• 67159-08-4 7-methyl-2-phenyl-1H-[1,8]naphthyridin-4-one 
• 85808-43-1 6-Methyl-2-phenyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one 
• 109274-77-3 6-Methyl-4-oxo-2-phenyl-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde 

Relevant academic research and scientific papers

Practical synthesis of 4H-pyrido[1, 2-a]pyrimidin-4-ones using ethylene glycol as a promoting solvent

A simple and useful protocol leading to different 4H-pyrido[1, 2-a] pyrimidin-4-ones have been established by cyclization of various 2-amino pyridines with β-oxo ester or alkynoate. The use of ethylene glycol was demonstrated to facilitate this condensati

Simple and efficient protocol for synthesis of pyrido[1,2-a]pyrimidin-4-one derivatives over solid heteropolyacid catalysts

Aluminium exchanged tungstophosphoric acid salts with Keggin structure (AlxH3-xPW12O40) were prepared by simple ion exchange method. The prepared heteropolyacid salts were characterized by various techniques suc

COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF

The compounds according to formula (I), their pharmaceutically acceptable acid or base addition salts, and the uses thereof. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for preparing medicaments for modula

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Macrocyclic peptides are disclosed having the general formula: wherein R′, R3, R3′, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula (I) wherein A, R2, R3, R', B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.

Condensation of substituted 2-aminopyridine with β-ketocarboxylic esters: 4H-pyrido[1,2-a]pyrimidin-4-ones and pyridin-2-ones

We report the condensation of substituted 2-aminopyridines 5 with β- ketocarboxylic esters in polyphosphoric acid. In this reaction were obtained together with the target compounds, 4H-pyrido[1,2-a]pyrimidin-4-ones 6 also the pyridin-2-ones 7. All the compounds 7 were tested for their calcium- antagonistic activity but failed to evoke any vasorelaxant response.